

STAND. COM. REP. NO. 853-16

Honolulu, Hawaii
March 4, 2016

RE: H.B. No. 254
H.D. 2

Honorable Joseph M. Souki
Speaker, House of Representatives
Twenty-Eighth State Legislature
Regular Session of 2016
State of Hawaii

Sir:

Your Committee on Consumer Protection & Commerce, to which was referred H.B. No. 254, H.D. 1, entitled:

"A BILL FOR AN ACT RELATING TO MEDICINES,"

begs leave to report as follows:

The purpose of this measure is to allow for the regulation of biosimilar medicines to ensure patient safety and access to medicines at lower prices.

The Alliance for Patient Access, Express Scripts, Global Healthy Living Foundation, Alliance for Safe Biologic Medicines, American Autoimmune Related Diseases Association, Inc., International Cancer Advocacy Network, National Hispanic Medical Association, National Patient Advocate Foundation, Biosimilars Council, Pharmaceutical Research and Manufacturers of America, Hawaii Medical Association, Alliance of Specialty Medicine, Global Colon Cancer Association, Lupus and Allied Diseases Association, Coalition of State Rheumatology Organizations, National Psoriasis Foundation, Biotechnology Innovation Organization, American Cancer Society Cancer Action Network, Arthritis Foundation, Pacific Region, National Organization for Rare Disorders, and a few individuals testified in support of this measure. The Department of the Attorney General, Hawaii Medical Service Association, and CVS Health provided comments on this measure.

HB254 HD2 HSCR CPC HMS 2016-2229



Your Committee has amended this measure by:

- (1) Specifying that within five business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's designee shall communicate to the prescriber the specific product provided to the patient;
- (2) Changing the effective date to July 1, 2112; and
- (3) Making technical, nonsubstantive amendments for clarity, consistency, and style.

As affirmed by the record of votes of the members of your Committee on Consumer Protection & Commerce that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 254, H.D. 1, as amended herein, and recommends that it pass Third Reading in the form attached hereto as H.B. No. 254, H.D. 2.

Respectfully submitted on
behalf of the members of the
Committee on Consumer
Protection & Commerce,



ANGUS L.K. MCKELVEY, Chair



